Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: Results from the Prostate Cancer Prevention Trial

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1500-1506

  Tang, Li ^a   Yao, Song ^a   Till, Cathee ^b   Goodman, Phyllis J ^b   Tangen, Catherine M ^c   Wu, Yue ^a   Kristal, Alan R ^b   Platz, Elizabeth A ^c   Neuhouser, Marian L ^b   Stanczyk, Frank Z ^d   Reichardt, Juergen K V ^e   Santella, Regina M ^f   Hsing, Ann ^g   Hoque, Ashraful ^h   Lippman, Scott M ^h   Thompson, Ian M ⁱ   Ambrosone, Christine B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e JAMES COOK UNIVERSITY   (Australia)

^f Mailman School of Public Health   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ University of Texas Health Science Center at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ESTRADIOL; ESTROGEN; ESTRONE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; ARTICLE; BIOSYNTHESIS; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; HORMONE BLOOD LEVEL; HORMONE METABOLISM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL;

AROMATASE; CASE-CONTROL STUDIES; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; DNA; ESTRADIOL; ESTROGENS; ESTRONE; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS; TESTOSTERONE;

EID: 80053153629     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr139     Document Type: Article

References (38)

1. Siegel,R. et al. (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-236.
2. Bostwick,D.G. et al. (2004) Human prostate cancer risk factors. Cancer, 101, 2371-2490.
3. Hsing,A.W. (2001) Hormones and prostate cancer: what's next? Epidemiol. Rev., 23, 42-58.
4. Sharifi,N. et al. (2005) Androgen deprivation therapy for prostate cancer. JAMA, 294, 238-244.
5. Ntais,C. et al. (2003) Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur. J. Endocrinol., 149, 469-477.
6. Ho,S.M. (2004) Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem., 91, 491-503.
7. Rogan,E.G. et al. (2004) Estrogen metabolites, conjugates, and DNA adducts: possible biomarkers for risk of breast, prostate, and other human cancers. Adv. Clin. Chem., 38, 135-149.
8. Yuen,M.T. et al. (2005) Enhanced induction of prostatic dysplasia and carcinoma in Noble rat model by combination of neonatal estrogen exposure and hormonal treatments at adulthood. Int. J. Oncol., 27, 1685-1695.
9. McPherson,S.J. et al. (2001) Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology, 142, 2458-2467.
10. Roddam,A.W. et al. (2008) Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J. Natl Cancer Inst., 100, 170-183.
11. Eaton,N.E. et al. (1999) Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br. J. Cancer, 80, 930-934.
12. Shaneyfelt,T. et al. (2000) Hormonal predictors of prostate cancer: a meta-analysis. J. Clin. Oncol., 18, 847-853.
13. Yao,S. et al. (2011) Serum estrogen levels and prostate cancer risk in the Prostate Cancer Prevention Trial: a nested case-control study. Cancer Causes Control, 22, 1121-1131.
14. Ellem,S.J. et al. (2004) Local aromatase expression in human prostate is altered in malignancy. J. Clin. Endocrinol. Metab., 89, 2434-2441.
15. Payne,A.H. et al. (2004) Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr. Rev., 25, 947-970.
16. Means,G.D. et al. (1989) Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem., 264, 19385-19391.
17. Yager,J.D. et al. (1996) Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 36, 203-232.
18. Cheng,Z. et al. (1998) Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol. Sci., 45, 52-57.
19. Thompson,I.M. et al. (2003) The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 349, 215-224.
20. Kristal,A.R. et al. (2008) Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol., 168, 1416-1424.
21. Rothman,K. et al. (1998) Modern Epidemiology. Lippincott Williams & Wilkins, Philadelphia, PA.
22. Gennari,L. et al. (2004) A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J. Clin. Endocrinol. Metab., 89, 2803-2810.
23. Haiman,C.A. et al. (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int. J. Cancer, 87, 204-210.
24. Piras,I. et al. (2008) Frequencies of promoter pentanucleotide (TTTTA)n of CYP11A gene in European and North African populations. Genet. Test., 12, 93-96.
25. Mooser,V. et al. (1995) Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma. Hum. Mol. Genet., 4, 173-181.
26. Celhar,T. et al. (2008) The presence of the CYP11A1 (TTTTA)6 allele increases the risk of biochemical relapse in organ confined and low-grade prostate cancer. Cancer Genet. Cytogenet., 187, 28-33.
27. Cicek,M.S. et al. (2005) Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11alpha in prostate cancer risk and aggressiveness. Cancer Epidemiol. Biomarkers Prev., 14, 2173-2177.
28. Cunningham,J.M. et al. (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol. Biomarkers Prev., 16, 969-978.
29. Douglas,J.A. et al. (2005) Identifying susceptibility genes for prostate cancer- a family-based association study of polymorphisms in CYP17, CYP19, CYP11A1, and LH-beta. Cancer Epidemiol. Biomarkers Prev., 14, 2035-2039.
30. Kumazawa,T. et al. (2004) Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer. Int. J. Cancer, 110, 140-144.
31. Kristensen,V.N. et al. (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene, 19, 1329-1333.
32. Cussenot,O. et al. (2007) Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J. Clin. Oncol., 25, 3596-3602.
33. Latil,A.G. et al. (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer, 92, 1130-1137.
34. Li,L. et al. (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 2280-2281.
35. Beutler,E. et al. (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl Acad. Sci. USA, 95, 8170-8174.
36. Fang,J.L. et al. (2004) Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo (a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol. Biomarkers Prev., 13, 102-109.
37. Karatzas,A. et al. (2010) Genetic polymorphisms in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and prostate cancer risk in Caucasian men. Cancer Epidemiol., 34, 345-349.
38. van Landeghem,A.A. et al. (1985) Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res., 45, 2900-2906.